Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1993 Jan;36(1):1–8. doi: 10.1007/BF01789124

Specific immune recognition of autologous tumor by lymphocytes infiltrating colon carcinomas: Analysis by cytokine secretion

Sophia S Hom 1, Steven A Rosenberg 1, Suzanne L Topalian 1,✉
PMCID: PMC11038069  PMID: 8422663

Abstract

Tumor-infiltrating lymphocytes (TIL) were grown in the presence of interleukin-2 from 19 colon carcinoma specimens, including 1 primary lesion and 18 metastatic lesions. These cultures showed a median proliferation of 606-fold (range 13-fold to 28 000-fold) over 49 culture days (range 26–76 days). By phenotype, mature cultures were 69%–99% CD3+ (mean 93%) and contained mixed populations of CD4+ and CD8+ cells (CD4>CD8 in 10 of 19 cultures). Fresh cryopreserved colon tumors were not lysed by autologous TIL in short-term51Cr-release assays, and were poorly lysed by lymphokine-activated killer cells. Ten TIL cultures were assayed for cytokine secretion in response to autologous and allogeneic tumors during a 6- to 24-h coincubation. Culture supernatants were tested by ELISA for the presence of granulocyte/macrophage-colony-stimulating factor, interferon γ, and tumor necrosis factor α. Of 10 TIL, 4 secreted at least two of these cytokines specifically in response to autologous and/or HLA-matched fresh allogeneic colon carcinomas, but not to melanomas or HLA-unmatched colon carcinomas. Cytokine secretion was mediated by both CD4+ and CD8+ TIL, and could be inhibited by mAb directed against the appropriate class of MHC antigen. These data provide evidence for specific, MHC-restricted immune recognition of human colon carcinomas by T lymphocytes.

Key words: Colon carcinoma, Tumor-infiltrating lymphocytes, Cytokines

References

  • 1.Aebersold P, Hyatt C, Johnson S, Hines K, Korcak L, Sanders M, Lotze MT, Topalian SL, Yang JC, Rosenberg SA. Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response. JNCI. 1991;83:932. doi: 10.1093/jnci/83.13.932. [DOI] [PubMed] [Google Scholar]
  • 2.Barth RJ, Jr, Mulé JJ, Spiess PJ, Rosenberg SA. Interferon-γ and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med. 1991;173:647. doi: 10.1084/jem.173.3.647. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Carrel S, Schmidt-Kessen S, Giuffre L. Recombinant interferon-γ can induce the expression of HLA-A,B,C and tumor associated antigens. Eur J Immunol. 1985;15:118. doi: 10.1002/eji.1830150204. [DOI] [PubMed] [Google Scholar]
  • 4.Chong AS-F, Scuderi P, Grimes WJ, Hersh EM. Tumor targets stimulate IL-2 activated killer cells to produce interferon-γ and tumor necrosis factor. J Immunol. 1989;142:2133. [PubMed] [Google Scholar]
  • 5.Grabstein KH, Urdal DL, Tucshinski RJ, Mochizuki R, Price L, Cantrell MA, Gillis S, Conlon PJ. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor. Science. 1986;232:506. doi: 10.1126/science.3083507. [DOI] [PubMed] [Google Scholar]
  • 6.Hom SS, Topalian SL, Simonis T, Mancini M, Rosenberg SA. Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen restriction. J Immunother. 1991;10:153. [PubMed] [Google Scholar]
  • 6a.Hom SS, Schwartzentruber DS, Rosenberg SA, Topalian SL (1992) Specific release of cytokines by lymphocytes infiltrating human melanomas in response to shared melanoma antigens. J Immunother (in press) [DOI] [PubMed]
  • 7.Hutchinson GH, Heinemann D, Symes MO, Williamson CN. Differential immune reactivity of tumor-intrinsic and peripheralblood lymphocytes against autoplastic colorectal carcinoma cells. Br J Cancer. 1981;44:396. doi: 10.1038/bjc.1981.197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.McDougall CJ, Ngoi SS, Goldman IS, Godwin T, Felix J, DeCosse JJ, Rigas B. Reduced expression of HLA class I and II antigens in colon cancer. Cancer Res. 1990;50:8023. [PubMed] [Google Scholar]
  • 9.Paliard X, Malefijt RDW, Yssel H, Blanchard HD, Chretien I, Abrams J, DeVries J, Spits H. Simultaneous production of IL-2, IL-4, and IFNγ by activated human CD4+ and CD8+ T cell clones. J Immunol. 1988;141:849. [PubMed] [Google Scholar]
  • 10.Pawelec G, Schaudt K, Rehbein A, Busch WF. Differential secretion of tumor necrosis factor-α and granulocyte/macrophage colony-stimulating factors but not interferon-γ from CD4+ compared to CD8+ human T cell clones. Eur J Immunol. 1989;19:197. doi: 10.1002/eji.1830190132. [DOI] [PubMed] [Google Scholar]
  • 11.Pfizinmaier K, Scheurich P, Schulter C, Kronke M. Tumor necrosis factor enhances HLA-A,B,C and HLA-DR gene expression in human tumor cells. J Immunol. 1987;138:975. [PubMed] [Google Scholar]
  • 12.Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee R, Rubin JT, Seipp CA, Simpson GC, White DE. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin 2 alone. N Engl J Med. 1987;316:889. doi: 10.1056/NEJM198704093161501. [DOI] [PubMed] [Google Scholar]
  • 13.Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp C, Simpson C, Carter C, Bock S, Schwartzentruber DJ, Wei JP, White DE. Use of tumor infiltrating lymphocytes and interleukin 2 in the immunotherapy of patients with metastatic melanoma: a preliminary report. N Engl J Med. 1988;319:1676. doi: 10.1056/NEJM198812223192527. [DOI] [PubMed] [Google Scholar]
  • 14.Schwartzentruber DJ, Topalian SL, Mancini M, Rosenberg SA. Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-α, and IFNγ by human tumor infiltrating lymphocytes after autologous tumor stimulation. J Immunol. 1991;146:3674. [PubMed] [Google Scholar]
  • 15.Schwartzentruber DJ, Solomon D, Rosenberg SA, Topalian SL. Characterization of lymphocytes infiltrating human breast cancer: specific immune reactivity can be detected by measuring cytokine secretion. J Immunother. 1992;12:1. doi: 10.1097/00002371-199207000-00001. [DOI] [PubMed] [Google Scholar]
  • 16.Schwartzentruber DJ, Stetler-Stevenson MJ, Rosenberg SA, Topalian SL. Specific antitumor immune reactivity by T cells infiltrating human B cell lymphomas (abstract) Proc Am Assoc Cancer Res. 1992;33:309. [Google Scholar]
  • 17.Shimizu Y, Iwatsuk S, Herberman RB, Whiteside TL. Effects of cytokines on in vitro growth of tumor-infiltrating lymphocytes obtained from human primary and metastatic liver tumors. Cancer Immunol Immunother. 1991;32:280. doi: 10.1007/BF01789045. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Sugarman BJ, Aggarwal BB, Hass PE, Frgani IS, Palladino MA, Shepard HM. Recombinant TNFα: effects on proliferation of normal and transformed cells in vitro. Science. 1985;230:943. doi: 10.1126/science.3933111. [DOI] [PubMed] [Google Scholar]
  • 19.Svennevig JL, Lunde OC, Holter J, Bjorgsvik D. Lymphoid infiltration and prognosis in colorectal carcinoma. Br J Cancer. 1984;49:375. doi: 10.1038/bjc.1984.60. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Topalian SL, Muul LM, Solomon D, Rosenberg SA. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods. 1987;102:127. doi: 10.1016/s0022-1759(87)80018-2. [DOI] [PubMed] [Google Scholar]
  • 21.Tyring S, Klimpel GR, Fleischmann WR, Baron S. Direct cytolysis by partially purified preparations of immune IFN. Int J Cancer. 1982;30:59. doi: 10.1002/ijc.2910300111. [DOI] [PubMed] [Google Scholar]
  • 22.Werkmeister JA, Pihl E, Nind APP, Flannery GR, Nairn RC. Immunoreactivity by intrinsic lymphoid cells in colorectal carcinoma. Br J Cancer. 1979;40:839. doi: 10.1038/bjc.1979.274. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Yoo Y-K, Heo DS, Hata K, Van Thiel DH, Whiteside TL. Tumor-infiltrating lymphocytes from human colon carcinomas: functional and phenotypic characteristics after long-term culture in recombinant interleukin 2. Gastroenterology. 1990;98:259. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES